<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937400</url>
  </required_header>
  <id_info>
    <org_study_id>20-08022572</org_study_id>
    <secondary_id>R01CA244500</secondary_id>
    <nct_id>NCT04937400</nct_id>
  </id_info>
  <brief_title>Delirium in Children Undergoing Stem Cell Transplantation</brief_title>
  <official_title>Delirium in Children Undergoing Stem Cell Transplantation: Epidemiology and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children undergoing stem cell transplants are at risk for delirium, a temporary change in&#xD;
      thinking and behavior. This study will define delirium rates, risk factors, and outcomes. Our&#xD;
      eventual goal is to reduce delirium in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delirium -- defined as an acute change in awareness and cognition that occurs in the setting&#xD;
      of an underlying illness -- is a common complication of hematopoietic stem cell&#xD;
      transplantation (HSCT) in adults, with associated morbidity and mortality. This has never&#xD;
      been studied in children, where risk factors may vary substantially from adults. The&#xD;
      objectives of this study are: to define the epidemiology of delirium, and measure its effect&#xD;
      on outcomes.&#xD;
&#xD;
      This prospective longitudinal cohort study will prospectively establish the incidence of&#xD;
      delirium in 1000 children in the peri-transplant period, and identify modifiable risk factors&#xD;
      that predispose to delirium development. This study will also define the effect of delirium&#xD;
      on important clinical outcomes, including neurocognitive function. This study will be&#xD;
      executed by a research consortium of five leading pediatric oncologic transplant centers in&#xD;
      North America, in collaboration with the leading pediatric delirium research group in the&#xD;
      United States.&#xD;
&#xD;
      This innovative proposal will leverage the combined experience of the pediatric delirium and&#xD;
      HSCT teams to expand urgently needed delirium research into a unique and unstudied&#xD;
      population. By reducing delirium rates, outcomes after pediatric HSCT can be optimized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Delirium incidence</measure>
    <time_frame>1-50 days</time_frame>
    <description>Number of patients who develop delirium during the course of their transplant hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>1-365 days</time_frame>
    <description>Length of transplant hospitalization will be measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>1-5 years</time_frame>
    <description>Count will include number of patients with either in-hospital or post-discharge mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rate</measure>
    <time_frame>1-365 days</time_frame>
    <description>Count will include number of patients who are readmitted to the hospital within 30-days of discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neurocognitive functioning as measured by the NIH Toolbox Cognition Battery</measure>
    <time_frame>pre-transplant, 3 months after transplant, 12 months after transplant</time_frame>
    <description>Neurocognitive functioning will be measured by the NIH Toolbox Cognition Battery, and reported as a total composite score ranging from 50-150. An average score, adjusted for age, is 100. A score lower than 100 indicates lower cognitive functioning than average; a score higher than 100 indicates higher cognitive functioning than average.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Pediatric Stem Cell Transplant Patients</arm_group_label>
    <description>A consecutive cohort of children admitted to the hospital for stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Daily screening for delirium</intervention_name>
    <description>Each child will be screened twice daily for delirium throughout the transplant hospitalization</description>
    <arm_group_label>Pediatric Stem Cell Transplant Patients</arm_group_label>
    <other_name>Cornell Assessment for Pediatric Delirium</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will include all patients admitted to the five participating pediatric stem cell&#xD;
        transplant sites for the purpose of HSCT during the study period. Enrollment goal is 1000&#xD;
        subjects overall, and 240 subjects for neurocognitive testing. Subjects will be seriously&#xD;
        ill. Every patient admitted for HSCT will be eligible for inclusion, unless they are &gt;21&#xD;
        years old. Subjects will be enrolled regardless of gender, race, or ethnicity. No subgroups&#xD;
        will be excluded, as delirium likely affects children of all ages and developmental&#xD;
        trajectories, with no predilection based on gender, race, or ethnicity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 0-21 years old&#xD;
&#xD;
          -  Admitted for purpose of stem cell transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt;21 years old&#xD;
&#xD;
          -  Admitted for reason other than stem cell transplant (example: late post-transplant&#xD;
             complications).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chani Traube</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chani Traube</last_name>
    <phone>2127463030</phone>
    <email>chr9008@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keshia Small</last_name>
    <email>kes4002@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandhya Kharbanda</last_name>
      <email>Sandhya.Kharbanda@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Sandhya Kharbanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Duncan</last_name>
      <email>Christine_Duncan@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Duncan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chani Traube</last_name>
      <email>chr9008@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Chani Traube, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Freedman</last_name>
      <email>FreedmanJ@chop.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Hurley</last_name>
      <email>Caitlin.Hurley@STJUDE.ORG</email>
    </contact>
    <investigator>
      <last_name>Caitlin Hurley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yogi Chopra</last_name>
      <email>yogi.chopra@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Yogi Chopra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Traube C, Gerber LM, Mauer EA, Small K, Broglie L, Chopra YR, Duncan CN, Ebens CL, Fitzgerald JC, Freedman JL, Hudspeth MP, Hurley C, Mahadeo KM, McArthur J, Shapiro MC, Sharron MP, Wall DA, Zinter MS, Greenwald BM, Silver G, Boulad F. Delirium in Children Undergoing Hematopoietic Cell Transplantation: A Multi-Institutional Point Prevalence Study. Front Oncol. 2021 Apr 22;11:627726. doi: 10.3389/fonc.2021.627726. eCollection 2021.</citation>
    <PMID>33968727</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>stem cell transplant</keyword>
  <keyword>outcomes</keyword>
  <keyword>epidemiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>All the participating researchers have made a commitment to publish, in a timely manner, all the relevant scientific information that they will derive during this project. Unpublished information could be made available to interested parties via a request to the Principal Investigator, in writing, to the address below, or by email.&#xD;
Chani Traube, MD Professor of Pediatrics Joan &amp; Sanford I Weill Medical College of Cornell University 1300 York Avenue New York, N.Y. 10065-4805 Phone: 212-746-3056 Email: chr9008@med.cornell.edu&#xD;
The sharing of unpublished information may be subject to confidentiality issues relating to our collaborations with other scientists in academic or corporate laboratories, and will need to be discussed with the appropriate institutions before any request is granted, wholly or in part.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

